Aldeyra Therapeutics (ALDX) Amortizatization of Intangibles (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Amortizatization of Intangibles came in at -$887215.0 in Q4 2025, down 157.7% YoY from $1.5 million in Q4 2024, and down 432.84% on a QoQ basis from $266560.0 in Q3 2025.
Aldeyra Therapeutics (ALDX) Amortizatization of Intangibles (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Amortizatization of Intangibles data on file, last reported at -$887215.0 in Q4 2025.
- Quarterly Amortizatization of Intangibles fell 157.7% year-over-year to -$887215.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $151103.0 (down 91.01% YoY) and the FY2025 annual result came in at $218260.0, down 86.94% from the prior year.
- Amortizatization of Intangibles fell to -$887215.0 in Q4 2025, from $266560.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.5 million in Q4 2024 to a low of -$887215.0 in Q4 2025.
- A 5-year average of $165780.9 and a median of $82799.5 in 2021 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles slumped 308.89% — and 2024, when it jumped 536.8%.
- Tracing ALDX's Amortizatization of Intangibles over 5 years: stood at $82799.0 in 2021, then declined by 0.06% to $82753.0 in 2022, then soared by 310.44% to $339651.0 in 2023, then surged by 352.69% to $1.5 million in 2024, then slumped by 157.7% to -$887215.0 in 2025.
- The last three Amortizatization of Intangibles figures came in at -$887215.0 (Q4 2025), $266560.0 (Q3 2025), and $771758.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,368.00 |
| Mar 31, 2026 | 50,368.00 |
| Dec 31, 2025 | -887,215.00 |
| Dec 31, 2025 | -887,215.00 |
| Sep 30, 2025 | 266,560.00 |
| Sep 30, 2025 | 266,560.00 |
| Jun 30, 2025 | 771,758.00 |
| Jun 30, 2025 | 771,758.00 |
| Mar 31, 2025 | 67,157.00 |
| Mar 31, 2025 | 67,157.00 |
| Dec 31, 2024 | 1.54 Mn |
| Dec 31, 2024 | 1.54 Mn |
| Sep 30, 2024 | -563,708.00 |
| Sep 30, 2024 | -563,708.00 |
| Jun 30, 2024 | 638,967.00 |
| Jun 30, 2024 | 638,967.00 |
| Mar 31, 2024 | 58,152.00 |
| Mar 31, 2024 | 58,152.00 |
| Dec 31, 2023 | 339,651.00 |
| Dec 31, 2023 | 339,651.00 |